Company intelligence / Profile preview
ProMIS Neurosciences
Toronto, Ontario, Canadapromisneurosciences.com ↗
- Ownership
- Public · PMN
- Development stage
- Other
01
Overview
Lead candidate PMN310 has completed Phase 1a clinical study and is currently in Phase 1b clinical trial (PRECISE-AD) in Alzheimer's disease patients. The Phase 1b trial is assessing safety, tolerability, and pharmacokinetics over 12 months in 100 patients with mild cognitive impairment due to AD or early AD.
- Therapeutic areas
- Neurology
- Modalities
- Antibody therapeuticsintrabodiesvectorized intrabodiesASOsvaccines
- Industry
- Biotech
02
Drug pipeline
13 assets12 more assets in the full pipeline.
03
Financials
- Market cap
- $32.7M
- Total revenue
- $0
- Enterprise value
- $-20.7M
Beyond the preview
Go deeper on ProMIS Neurosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ProMIS Neurosciences.